Terms: = Sarcomas AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Prognosis
13 results:
1. The Effects of Fucoidan Derived from
Gupta D; Martinez DC; Puertas-Mejía MA; Hearnden VL; Reilly GC
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396762
[TBL] [Abstract] [Full Text] [Related]
2. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
Yan Q; Yao WT; Du XH; Guo LY; Fan YC
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
[No Abstract] [Full Text] [Related]
3. Tandem mass tag (TMT) quantitative protein analysis-based proteomics and parallel reaction monitoring (PRM) validation revealed that MST4 accelerates osteosarcoma proliferation by increasing MRC2 activity.
Liu Y; Zhang X; Ren X; Sun J; Wen Y; Guo Z; Ma Q
Mol Carcinog; 2023 Sep; 62(9):1338-1354. PubMed ID: 37378424
[TBL] [Abstract] [Full Text] [Related]
4. The FBXO32/atr/ATM axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression.
Lu Y; Huang P; Li Y; Liu W; Li J; Zhao R; Feng H; Shi C; Cao G
Acta Biochim Biophys Sin (Shanghai); 2023 May; 55(5):842-852. PubMed ID: 37227155
[TBL] [Abstract] [Full Text] [Related]
5. A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes.
Tang H; Liu S; Luo X; Sun Y; Li X; Luo K; Liao S; Li F; Liang J; Zhan X; Wei Q; Liu Y; He M
Front Immunol; 2023; 14():1150588. PubMed ID: 37090691
[TBL] [Abstract] [Full Text] [Related]
6. Sarcoma brain metastases: Tertiary cancer center experience.
Ababneh HS; Muhsen B; Fares AS; Hirbawi H; Awabdeh TA; Hussaini MA; Amarin R; Mousa AA; Salah S
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S758-S763. PubMed ID: 38384052
[TBL] [Abstract] [Full Text] [Related]
7. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Dimitriou F; Namikawa K; Reijers ILM; Buchbinder EI; Soon JA; Zaremba A; Teterycz P; Mooradian MJ; Armstrong E; Nakamura Y; Vitale MG; Tran LE; Bai X; Allayous C; Provent-Roy S; Indini A; Bhave P; Farid M; Kähler KC; Mehmi I; Atkinson V; Klein O; Stonesifer CJ; Zaman F; Haydon A; Carvajal RD; Hamid O; Dummer R; Hauschild A; Carlino MS; Mandala M; Robert C; Lebbe C; Guo J; Johnson DB; Ascierto PA; Shoushtari AN; Sullivan RJ; Cybulska-Stopa B; Rutkowski P; Zimmer L; Sandhu S; Blank CU; Lo SN; Menzies AM; Long GV
Ann Oncol; 2022 Sep; 33(9):968-980. PubMed ID: 35716907
[TBL] [Abstract] [Full Text] [Related]
8. The impact of miR-9 in osteosarcoma: A study based on meta-analysis, TCGA data, and bioinformatics analysis.
Wu F; Jiang X; Wang Q; Lu Q; He F; Li J; Li X; Jin M; Xu J
Medicine (Baltimore); 2020 Aug; 99(35):e21902. PubMed ID: 32871922
[TBL] [Abstract] [Full Text] [Related]
9. Hsa_circ_0003732 promotes osteosarcoma cells proliferation via miR-545/CCNA2 axis.
Li L; Kong XA; Zang M; Dong J; Feng Y; Gui B; Hu Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32537647
[TBL] [Abstract] [Full Text] [Related]
10. atr Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status.
Laroche-Clary A; Chaire V; Verbeke S; Algéo MP; Malykh A; Le Loarer F; Italiano A
Sci Rep; 2020 May; 10(1):7488. PubMed ID: 32366852
[TBL] [Abstract] [Full Text] [Related]
11. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract] [Full Text] [Related]
12. Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis.
Lawlor RT; Veronese N; Pea A; Nottegar A; Smith L; Pilati C; Demurtas J; Fassan M; Cheng L; Luchini C
BMC Cancer; 2019 Mar; 19(1):232. PubMed ID: 30871494
[TBL] [Abstract] [Full Text] [Related]
13. HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas.
Ernst A; Anders H; Kapfhammer H; Orth M; Hennel R; Seidl K; Winssinger N; Belka C; Unkel S; Lauber K
Cancer Lett; 2015 Sep; 365(2):211-22. PubMed ID: 26044951
[TBL] [Abstract] [Full Text] [Related]
